AR006309A1 - Derivados de pirrolidina, antagonistas de endotelina, composiciones farmaceuticas, uso de dichos derivados para la preparacion de medicamentos y procedimientos para preparar dichos derivados - Google Patents

Derivados de pirrolidina, antagonistas de endotelina, composiciones farmaceuticas, uso de dichos derivados para la preparacion de medicamentos y procedimientos para preparar dichos derivados

Info

Publication number
AR006309A1
AR006309A1 ARP970100553A ARP970100553A AR006309A1 AR 006309 A1 AR006309 A1 AR 006309A1 AR P970100553 A ARP970100553 A AR P970100553A AR P970100553 A ARP970100553 A AR P970100553A AR 006309 A1 AR006309 A1 AR 006309A1
Authority
AR
Argentina
Prior art keywords
derivatives
lower alkyl
hydrogen
arylalkyl
alkyl
Prior art date
Application number
ARP970100553A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR006309A1 publication Critical patent/AR006309A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Antagonista de endotelina derivados de pirrolidina que tienen la fórmula (I), donde Z es -C(R18)(R19)- o -C(O)- donde R18 y R19 estánindependientemente seleccionados entre hidrógeno y alquilo inferior; R es -(CH2)m-W donde m es unen tero de 0 a 6 y W es -C(O)2-G donde G es hidrógenoo un grupo protector carboxi; -PO3H3; -P(O)(OH)E donde E es hidrógeno, alquilo inferior o arilalquilo; -CN; -C(O)NHR17 donde R17 es alquilo inferior;alquilaminocarbonilo;dialquilaminocarboni lo; tetrazolilo; hidroxi; alcoxi; sulfonamido; -C(O)NHS(O)2R16 donde R16 es alquilo inferior, haloalquilo,aril o dialquilamino -S(O)2NHC(O)R16 donde R16 es tal como se ha definido en lo que antecede, fórmulas de (n) a(u); R1 está independi entementeseleccionado de alquilo inferior, alquenilo, haloalquilo, cicloalquilo, arilalquilo, ariloxialquilo, arilalcoxialquilo, (N-alcanoil-N-alquilo)aminoalquilo, alquilsulfonilamidoalquilo y (heterocíclico)alquilo;R2 está independien temente seleccionado entre hidrógeno, alquilo inferior, alquenilo,alquinilo, alcoxialquil, alcoxicarbonilalquilo, hidroxialquilo, haloalquilo, alcoxialcoxialquilo, tioalcoxialcoxialquilo,(N-alcanoil-N-alquilo)aminoalquilo, alquilsulfonilamidoalqu ilo, cicloalquilo, cicloalquilalquilo, aminocarbonilalquilo, alquilaminocarbonilalquilo, dialquilaminocarbonilalquilo,aminocarbonilalquenilo, alquilaminocarbonilalquenilo,dialquilaminocarbonilalquenilo, hidroxialquenilo , arilo, arilalquilo,ariloxialquilo, arilalcoxialquilo, heterocíclico, alquilo (heterocíclico), y (Raa)(Rbb)NRcc- donde Raa es arilo arilalquilo, Rbb es hidrógeno o alcanoiloy Rcc es alquileno conla condición de que uno o ambos de R1 y R2 sean distintos de hidrógeno; R3 es R4-C(O)-R5; R4-R5a; R6-S(O)2-R7 o R26-S(O)-R27-
ARP970100553A 1996-02-13 1997-02-12 Derivados de pirrolidina, antagonistas de endotelina, composiciones farmaceuticas, uso de dichos derivados para la preparacion de medicamentos y procedimientos para preparar dichos derivados AR006309A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60062596A 1996-02-13 1996-02-13
US79450697A 1997-02-04 1997-02-04

Publications (1)

Publication Number Publication Date
AR006309A1 true AR006309A1 (es) 1999-08-25

Family

ID=27083659

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100553A AR006309A1 (es) 1996-02-13 1997-02-12 Derivados de pirrolidina, antagonistas de endotelina, composiciones farmaceuticas, uso de dichos derivados para la preparacion de medicamentos y procedimientos para preparar dichos derivados

Country Status (17)

Country Link
EP (2) EP0885215B1 (es)
JP (1) JP2002504081A (es)
KR (1) KR100508200B1 (es)
CN (2) CN1091768C (es)
AR (1) AR006309A1 (es)
AT (1) ATE323697T1 (es)
AU (1) AU2262097A (es)
BR (1) BR9707509A (es)
CA (2) CA2245587C (es)
CZ (1) CZ296660B6 (es)
DE (1) DE69735710T2 (es)
DK (1) DK0885215T3 (es)
ES (1) ES2259803T3 (es)
IL (2) IL125177A0 (es)
NZ (1) NZ330818A (es)
PT (1) PT885215E (es)
WO (1) WO1997030045A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
DE19743681A1 (de) * 1997-10-02 1999-04-08 Knoll Ag Methode zur Verhinderung der Transplantatabstoßung
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
WO2000004179A1 (en) * 1998-07-15 2000-01-27 Bristol-Myers Squibb Company Stereoselective reductive amination of ketones
CA2342217C (en) * 1998-09-14 2009-12-15 Abbott Laboratories Process for producing stereoselective nitro compounds
TWI306760B (en) * 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
WO2002017912A1 (en) * 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
JP4498133B2 (ja) 2002-07-02 2010-07-07 シェーリング コーポレイション 新規神経ペプチドｙｙ５レセプターアンタゴニスト
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
EP2190433A2 (en) 2007-08-22 2010-06-02 Gilead Colorado, Inc. Therapy for complications of diabetes
DK2227466T3 (da) * 2007-11-30 2011-08-08 Bayer Schering Pharma Ag Heteroaryl-substituerede piperidiner
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
MX368703B (es) 2013-02-28 2019-10-11 Amgen Inc Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
CA2906538C (en) 2013-03-14 2021-02-02 Ana Gonzalez Buenrostro Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
CN109400567A (zh) * 2018-12-05 2019-03-01 华中药业股份有限公司 一种合成甘草素的方法
MX2022007471A (es) 2019-12-17 2022-08-17 Chinook Therapeutics Inc Metodos de tratamiento de la nefropatia por iga con atrasentan.
CN116194449B (zh) * 2021-09-03 2024-07-26 深圳信立泰药业股份有限公司 一种内皮素a(eta)受体拮抗剂化合物及其制备方法和医药用途
WO2024022262A1 (zh) * 2022-07-25 2024-02-01 深圳信立泰药业股份有限公司 一种内皮素a(eta)受体拮抗剂化合物的盐及其制备方法和医药用途
WO2024092240A1 (en) 2022-10-28 2024-05-02 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0612244T3 (da) * 1991-11-05 2002-01-14 Smithkline Beecham Corp Endothelinreceptorantagonister
EP0650484B1 (en) * 1992-07-17 2000-01-26 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1996006095A1 (en) * 1994-08-19 1996-02-29 Abbott Laboratories Endothelin antagonists

Also Published As

Publication number Publication date
ATE323697T1 (de) 2006-05-15
IL125177A0 (en) 1999-03-12
DE69735710D1 (de) 2006-05-24
WO1997030045A1 (en) 1997-08-21
JP2002504081A (ja) 2002-02-05
DE69735710T2 (de) 2007-03-29
CN1091768C (zh) 2002-10-02
IL125177A (en) 2007-12-03
EP0885215B1 (en) 2006-04-19
KR100508200B1 (ko) 2005-12-16
CZ296660B6 (cs) 2006-05-17
BR9707509A (pt) 1999-07-27
CZ253798A3 (cs) 1999-07-14
CA2245587C (en) 2008-12-30
CA2634973A1 (en) 1997-08-21
PT885215E (pt) 2006-08-31
EP0885215A1 (en) 1998-12-23
CA2245587A1 (en) 1997-08-21
EP1609790A2 (en) 2005-12-28
CN1384100A (zh) 2002-12-11
EP1609790A3 (en) 2006-01-04
DK0885215T3 (da) 2006-08-14
ES2259803T3 (es) 2006-10-16
CN1219172A (zh) 1999-06-09
KR19990082514A (ko) 1999-11-25
NZ330818A (en) 2000-05-26
AU2262097A (en) 1997-09-02

Similar Documents

Publication Publication Date Title
AR006309A1 (es) Derivados de pirrolidina, antagonistas de endotelina, composiciones farmaceuticas, uso de dichos derivados para la preparacion de medicamentos y procedimientos para preparar dichos derivados
KR950010885A (ko) 골 손실의 억제 방법
EA199800404A1 (ru) Производные 1-(1,2-дизамещенный пиперидинил)-4-замещенного пиперазина
HK1042486B (zh) 新的脒衍生物，其製備方法，其作為藥物的用途以及含有該化合物的藥物組合物
BR9909666A (pt) Derivados de amida e antagonistas de nociceptina
BR9915534A (pt) 1-piridil substituìdo)-1,2,4-triazóis inseticidas
AR021995A1 (es) Derivados de quinolina 1,2-anelados.
BRPI0415433A (pt) derivados de n-[fenil (alquilpiperidin-2-il)metil] benzamida, seu preparo e sua aplicação em terapêutica
KR970704444A (ko) 트리아진 유도체 및 의약(triazine derivative and medicine)
ES476658A1 (es) Procedimiento para preparar derivados de sulfonamido-piridi-na
CA2238817A1 (en) 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
NZ214787A (en) Arylcyclobutylalkylamines and pharmaceutical compositions
RU98103160A (ru) Производные таксана
KR950010894A (ko) 자궁 섬유증의 억제 방법
AU539310B2 (en) Benzomorphan derivatives
AR016071A1 (es) Antagonistas de endotelina, composiciones farmaceuticas y uso de dichos compuestos para preparar medicamentos
AR005801A1 (es) Antagonistas de la endotelina, composicion farmaceutica que los contiene y uso de un compuesto antagonista para preparar un medicamento o composicionfarmaceutica
EP0375223A3 (en) Novel compounds
AR015141A1 (es) Derivados heterociclicos antagonistas de endotelina, composicion farmaceutica que los contiene, el uso de los mismos en la manufactura de un medicamento yprocedimiento para su preparacion
EP1344777A4 (en) IMIDAZOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR APPLICATION
BR9815348A (pt) " composto, uso deste ou de um sal farmacologicamente aceitável, éster ou outro derivado do mesmo, medicamento, agentes preventivos ou terapêuticos para asma e/ou bronquite, para rinite, para doença alérgica, e para incontinência urinária, e, processos de prevenção ou tratamento de asma e/ou bronquite, de rinite, de doença alérgica, e de incontinência urinária. "
HUP9902270A1 (hu) Analgetikus hatású akridinszármazékok, előállításuk és alkalmazásuk
EP1219619A4 (en) piperidine
KR960007560A (ko) 신규한 아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도
ID23521A (id) Turunan-turunan karbostiril

Legal Events

Date Code Title Description
FB Suspension of granting procedure